Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Phasebio Pharmaceuticals's Business Segments
Phasebio Pharmaceuticals's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Phasebio Pharmaceuticals does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Sublicense Revenue96.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Sublicense Revenue | $ 0 | 96.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Phasebio Pharmaceuticals
Phasebio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and metabolic diseases. The company was founded in 2002 and is headquartered in Malvern, Pennsylvania, United States.
Phasebio is committed to addressing unmet medical needs and improving patient outcomes through innovative treatment options. They emphasize developing therapies utilizing their proprietary elastin-like polypeptide (ELP) platform technology, which allows for the targeted and controlled release of therapeutic proteins in a sustained manner.
One of the main therapeutic areas that Phasebio focuses on is cardiovascular diseases, including conditions such as heart failure, acute myocardial infarction, and peripheral arterial disease. They believe that by developing therapies that can address the underlying causes of these diseases, they can significantly impact patient health and quality of life.
The company's lead product candidate is Bentracimab (PB2452), a novel, potent, and specific antidote for the antiplatelet drug Ticagrelor. Ticagrelor is commonly used to prevent blood clots in patients undergoing percutaneous coronary intervention (PCI) procedures. However, in emergency situations where bleeding needs to be stopped or reversed, such as major surgery or life-threatening bleeding events, there is currently no approved specific antidote. Bentracimab aims to fill this critical treatment gap.
Phasebio completed a successful Phase 1 clinical trial for Bentracimab, demonstrating its potential for rapid and sustained reversal of Ticagrelor's antiplatelet effects. The company is now progressing with Phase 2 and Phase 3 clinical trials to further evaluate and establish the safety and efficacy of Bentracimab.
In addition to Bentracimab, Phasebio has several other product candidates in its pipeline. PB1046, a weekly injectable therapy, is being developed for the treatment of pulmonary arterial hypertension (PAH), a life-threatening condition characterized by high blood pressure in the arteries of the lungs. PB1046 has shown promising results in Phase 2 clinical trials and is now advancing into Phase 3 trials.
Phasebio also has a preclinical pipeline, with product candidates targeting diseases such as type 2 diabetes, endocrine diseases, and rare genetic disorders. These early-stage projects demonstrate the company's commitment to expanding its portfolio and addressing a broad range of diseases.
To support its research and development efforts, Phasebio collaborates with academic institutions, clinical experts, and strategic partners in the pharmaceutical industry. By leveraging external expertise and resources, Phasebio aims to accelerate the development of its product candidates and bring them to market efficiently.
In summary, Phasebio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is leading the charge in developing novel therapies for cardiovascular and metabolic diseases. With a focus on its proprietary ELP platform technology and a strong pipeline of product candidates, Phasebio aims to transform patient care and improve health outcomes in these critical therapeutic areas.
Phasebio is committed to addressing unmet medical needs and improving patient outcomes through innovative treatment options. They emphasize developing therapies utilizing their proprietary elastin-like polypeptide (ELP) platform technology, which allows for the targeted and controlled release of therapeutic proteins in a sustained manner.
One of the main therapeutic areas that Phasebio focuses on is cardiovascular diseases, including conditions such as heart failure, acute myocardial infarction, and peripheral arterial disease. They believe that by developing therapies that can address the underlying causes of these diseases, they can significantly impact patient health and quality of life.
The company's lead product candidate is Bentracimab (PB2452), a novel, potent, and specific antidote for the antiplatelet drug Ticagrelor. Ticagrelor is commonly used to prevent blood clots in patients undergoing percutaneous coronary intervention (PCI) procedures. However, in emergency situations where bleeding needs to be stopped or reversed, such as major surgery or life-threatening bleeding events, there is currently no approved specific antidote. Bentracimab aims to fill this critical treatment gap.
Phasebio completed a successful Phase 1 clinical trial for Bentracimab, demonstrating its potential for rapid and sustained reversal of Ticagrelor's antiplatelet effects. The company is now progressing with Phase 2 and Phase 3 clinical trials to further evaluate and establish the safety and efficacy of Bentracimab.
In addition to Bentracimab, Phasebio has several other product candidates in its pipeline. PB1046, a weekly injectable therapy, is being developed for the treatment of pulmonary arterial hypertension (PAH), a life-threatening condition characterized by high blood pressure in the arteries of the lungs. PB1046 has shown promising results in Phase 2 clinical trials and is now advancing into Phase 3 trials.
Phasebio also has a preclinical pipeline, with product candidates targeting diseases such as type 2 diabetes, endocrine diseases, and rare genetic disorders. These early-stage projects demonstrate the company's commitment to expanding its portfolio and addressing a broad range of diseases.
To support its research and development efforts, Phasebio collaborates with academic institutions, clinical experts, and strategic partners in the pharmaceutical industry. By leveraging external expertise and resources, Phasebio aims to accelerate the development of its product candidates and bring them to market efficiently.
In summary, Phasebio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is leading the charge in developing novel therapies for cardiovascular and metabolic diseases. With a focus on its proprietary ELP platform technology and a strong pipeline of product candidates, Phasebio aims to transform patient care and improve health outcomes in these critical therapeutic areas.
PhaseBio Pharmaceuticals Inc. is a biopharmaceutical company primarily focused on the development and commercialization of innovative therapies for patients with rare diseases and serious conditions. The company seeks to leverage its proprietary technology platforms to create therapeutics that address unmet medical needs in various therapeutic areas, particularly within cardiology and metabolic diseases.
Segments
1. Cardiovascular Diseases: This segment primarily focuses on treating conditions related to the heart and blood vessels. PhaseBios pipeline includes therapies aimed at improving patient outcomes in acute and chronic cardiovascular conditions.
2. Metabolic Disorders: PhaseBio addresses rare metabolic disorders where existing treatment options may be limited. This segment involves the development of therapies that help manage or mitigate the effects of metabolic dysfunctions.
3. Rare Diseases: Recognizing the significant unmet needs within the rare diseases space, PhaseBio is dedicated to developing drugs that can provide meaningful benefits to patients suffering from these often overlooked conditions.
Products
1. PB2452: This is a reversible antagonist of ticagrelor used to reverse the antiplatelet effects of ticagrelor rapidly in patients who require urgent surgical intervention or who experience severe bleeding. Approved for specific scenarios, PB2452 is designed to enhance patient management in critical situations.
2. PB1046: This is a novel, long-acting peptide therapeutic designed for the treatment of heart failure and other cardiovascular conditions. PB1046 is engineered to provide sustained effects for the management of diseases characterized by chronic cardiovascular dysfunction.
3. PB201: This product candidate is aimed at treating specific metabolic disorders. PB201 is under development to provide a new therapeutic option for patients with genetic mutations that lead to severe metabolic dysregulation.
4. Pipeline Candidates: In addition to these main products, PhaseBio has several candidates in various stages of development, focusing on additional therapeutic areas that may include autoimmune disorders, neurodegenerative diseases, and other chronic conditions that require innovative therapeutic approaches.
Services
1. Clinical Development Services: PhaseBio engages in the planning and execution of clinical trials to ensure robust data collection and regulatory compliance, which is vitally important in the biopharmaceutical sector. They work to advance their products through the various phases of clinical testing, gathering evidence of safety and efficacy.
2. Regulatory Affairs: PhaseBio manages the necessary regulatory submissions and interactions with health authorities to facilitate the approval processes for its therapies. This includes preparing documentation for Investigational New Drug (IND) applications and New Drug Applications (NDAs).
3. Manufacturing Services: The company is involved in the production of its therapeutic candidates. This encompasses both the scale-up of manufacturing processes and adherence to Good Manufacturing Practices (GMP) to ensure product quality and consistency.
4. Collaborations and Partnerships: PhaseBio may also partner with other pharmaceutical companies, research institutions, and stakeholders in the healthcare ecosystem to enhance its research capabilities, access additional resources, and expand its developmental prospects.
5. Patient and Healthcare Provider Engagement: Patient advocacy and education are integral components of PhaseBios service offerings. The company actively seeks to engage with both patients and healthcare providers to ensure that those impacted by the diseases being targeted are aware of available therapies and ongoing clinical trials.
PhaseBio Pharmaceuticals Inc. is committed to advancing treatment options across these segments and maintaining a strong focus on the needs of patients with rare and serious diseases. Through their innovative approaches and the dedicated work of their teams, the company strives to make a significant impact in the field of biopharmaceuticals.
Segments
1. Cardiovascular Diseases: This segment primarily focuses on treating conditions related to the heart and blood vessels. PhaseBios pipeline includes therapies aimed at improving patient outcomes in acute and chronic cardiovascular conditions.
2. Metabolic Disorders: PhaseBio addresses rare metabolic disorders where existing treatment options may be limited. This segment involves the development of therapies that help manage or mitigate the effects of metabolic dysfunctions.
3. Rare Diseases: Recognizing the significant unmet needs within the rare diseases space, PhaseBio is dedicated to developing drugs that can provide meaningful benefits to patients suffering from these often overlooked conditions.
Products
1. PB2452: This is a reversible antagonist of ticagrelor used to reverse the antiplatelet effects of ticagrelor rapidly in patients who require urgent surgical intervention or who experience severe bleeding. Approved for specific scenarios, PB2452 is designed to enhance patient management in critical situations.
2. PB1046: This is a novel, long-acting peptide therapeutic designed for the treatment of heart failure and other cardiovascular conditions. PB1046 is engineered to provide sustained effects for the management of diseases characterized by chronic cardiovascular dysfunction.
3. PB201: This product candidate is aimed at treating specific metabolic disorders. PB201 is under development to provide a new therapeutic option for patients with genetic mutations that lead to severe metabolic dysregulation.
4. Pipeline Candidates: In addition to these main products, PhaseBio has several candidates in various stages of development, focusing on additional therapeutic areas that may include autoimmune disorders, neurodegenerative diseases, and other chronic conditions that require innovative therapeutic approaches.
Services
1. Clinical Development Services: PhaseBio engages in the planning and execution of clinical trials to ensure robust data collection and regulatory compliance, which is vitally important in the biopharmaceutical sector. They work to advance their products through the various phases of clinical testing, gathering evidence of safety and efficacy.
2. Regulatory Affairs: PhaseBio manages the necessary regulatory submissions and interactions with health authorities to facilitate the approval processes for its therapies. This includes preparing documentation for Investigational New Drug (IND) applications and New Drug Applications (NDAs).
3. Manufacturing Services: The company is involved in the production of its therapeutic candidates. This encompasses both the scale-up of manufacturing processes and adherence to Good Manufacturing Practices (GMP) to ensure product quality and consistency.
4. Collaborations and Partnerships: PhaseBio may also partner with other pharmaceutical companies, research institutions, and stakeholders in the healthcare ecosystem to enhance its research capabilities, access additional resources, and expand its developmental prospects.
5. Patient and Healthcare Provider Engagement: Patient advocacy and education are integral components of PhaseBios service offerings. The company actively seeks to engage with both patients and healthcare providers to ensure that those impacted by the diseases being targeted are aware of available therapies and ongoing clinical trials.
PhaseBio Pharmaceuticals Inc. is committed to advancing treatment options across these segments and maintaining a strong focus on the needs of patients with rare and serious diseases. Through their innovative approaches and the dedicated work of their teams, the company strives to make a significant impact in the field of biopharmaceuticals.